What is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of therapies for rare, debilitating, chronic neuromuscular, and neurological diseases within the United States. The company's portfolio includes Firdapse, an amifampridine phosphate tablet indicated for Lambert-Eaton Myasthenic Syndrome (LEMS), and Ruzurgi, targeting pediatric LEMS patients. Catalyst is also exploring Firdapse for MuSK antibody-positive myasthenia gravis and spinal muscular atrophy type. Strategic partnerships, including a license agreement with BioMarin Pharmaceutical Inc. and a collaboration with Endo Ventures Limited for generic Sabril tablets, highlight its approach to expanding its therapeutic reach and product pipeline. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals has established a focused presence in the rare disease market.
How much funding has Catalyst Pharmaceuticals raised?
Catalyst Pharmaceuticals has raised a total of $20.1M across 1 funding round:
Stock Offering
$20.1M
Stock Issuance/Offering (2006): $20.1M, investors not publicly disclosed
What's next for Catalyst Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal growth phase for Catalyst Pharmaceuticals. This capital infusion is likely earmarked for accelerating the commercialization of its existing therapies, expanding clinical trial pipelines for new indications such as MuSK antibody-positive myasthenia gravis and spinal muscular atrophy, and potentially exploring new rare disease targets. The company's strategic alliances suggest a continued focus on leveraging external partnerships for development and market access, positioning Catalyst for sustained expansion in the competitive biopharmaceutical landscape.
See full Catalyst Pharmaceuticals company page
